C6

glioma cells

Cell Type:
Glial Cells
Tissue Origin:
brain
Species:
rat
Research Area:
Cancer Research/Cell Biology
Neurobiology
Cell Characteristics:
Adherent

Recommended Media

PC-1™ is a low-protein, serum-free medium intended for the culture of primary cells and anchorage-dependent cell lines. PC-1 is formulated in a specially modified DMEM/F12 base and contains a complete HEPES buffering system with known amounts of insulin, transferrin, fatty acids, and proprietary proteins assembled under strict quality control procedures. PC-1™ is intended for a variety of research and industrial applications and is formulated using defined components for optimal cell growth, while maintaining the lowest possible protein content.
PC-1™ does not contain L-glutamine.

PC-1™ Liquid Base Medium is to be stored at 2°C-8°C.
The Supplement should be stored at -20°C.
When these two components are combined, the resulting PC-1™ Complete Medium is stable for 45 days at 2°C-8°C.

Once thawed, the appropriate volume of one vial of PC-1™ Supplement must be combined with the companion volume of PC-1™ Liquid Base Medium. Partial reconstitution or repeated freezing and thawing of the PC-1™ Supplement is not advised.

Transfection Information

Lonza Optimized Protocol
Optimization Guideline
Filter:
The table below shows data for the cell type and Nucleofector™ Platform selected. Those data are either based on Lonza Optimized Protocols or on results shared from customers who performed an optimization based on our guidelines. In case no data are shown for the selected Nucleofector™ Platform, please take a look at our optimization strategy to get further guidance on how to easily determine optimal Nucleofection conditions yourself.
Protocol Kit Program Cells Efficiency Viable Cells Substrate Format Platform
SF

FF-127

1e6 92% ±1 58% ± Plasmid (general) 5 µg 100 µl 4D X-Unit
SF

FF-127

2e5 93% ± 68% ± Plasmid (general) 1 µg 20 µl 4D X-Unit
V

U-009

2e6 70% ±6 80% Plasmid (general) 2 µg 100 µl I/II/2b
V U-009 2e6 87% ±2 80% Plasmid (general) 2 µg 100 µl I/II/2b
V U-030 2e6 91% ±2 75% Plasmid (general) 2 µg 100 µl I/II/2b
V U-030 2e6 94% ±3 75% Plasmid (general) 2 µg 100 µl I/II/2b

Citations (7)

Categories:
Transfection 
Authors:
Kouranova E, Forbes K, Zhao G, Warren J, Bartels A, Wu Y, Cui . 
In:
Hum Gene Ther (2016) 27(69: 464-75 
Categories:
Transfection 
Authors:
Larcher T, Lafoux A, Tesson L, Remy S, Thepenier V, François V, Le Guiner C, Goubin H, Dutilleul M, Guigand L, Toumaniantz G, De Cian A, Boix C, Renaud JB, Cherel Y, Giovannangeli C, Concordet JP, Anegon I, Huchet C. 
In:
PLoS ONE (2014) 9(10): e11037 
Categories:
Transfection 
Authors:
Lomonaco SL, Kahana S, Blass M, Brody Y, Okhrimenko H, Xiang C, Finniss S, Blumberg PM, Lee HK, Brodie C 
In:
J Biol Chem (2008) 283(25): 17731-9 
Categories:
Transfection 
Authors:
Choi BH, Kim CG, Bae YS, Lim Y, Lee YH, Shin SY 
In:
Cancer Res (2008) 68(5): 1369-77 
Categories:
Transfection 
Authors:
De Domenico I, Ward DM, di Patti MC, Jeong SY, David S, Musci G, Kaplan J 
In:
EMBO J (2007) 26(12): 2823-31 
Categories:
Transfection 
Authors:
Kapic A, Helmbold H, Reimer R, Klotzsche O, Deppert W and Bohn W 
In:
Cell Death Differ (2006) 13(2): 324-334 
Categories:
Transfection 
Authors:
Gresch O, Engel FB, Nesic D, Tran TT, England HM, Hickman ES, Korner I, Gan L, Chen S, Castro-Obregon S, Hammermann R, Wolf J, Muller-Hartmann H, Nix M, Siebenkotten G, Kraus G and Lun K 
In:
Methods (2004) 33(2): 151-163 
+ Show All